Jun Hou

Dr. Jun Hou


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2022 in Cancer Medicine
Verified
Journal Article
Open access
XLXuetao Li
Xuetao Li
YLYujun Li
Yujun Li
ZZZiwen Zhao
Ziwen Zhao
NMNabo Miao
Nabo Miao
GLGuorong Liu
Guorong Liu
JHJun Hou
Jun Hou
Introduction: The activation of STING (stimulator of interferon genes) pathway enhances antitumor immunity in small‐cell lung cancer (SCLC), while the DNA damage induced by non‐cGAMP‐based agonists is a potent inducer of STING activity. Here, we investigate the intrinsic expression of STING in cancer cells and evaluate the value of the combination of ATR and TOP1 inhibitors in enhancing antitumor immunity.Methods: STING expression was assessed at mRNA and protein levels in SCLC and normal lung tissues. Transcriptomic subsets of SCLC were identified based on STING‐related genes. Distinct mutation and immunogenomic profiles of these subsets were determined. The direct antitumor efficacy and the potential of enhancing antitumor immunity of the strategy using the ATR‐TOP1‐inhibitor combination were tested in SCLC cell lines.Results: The intrinsic expression of STING was significantly reduced in SCLC compared to normal lung tissues (p < 0.0001). Three STING‐related SCLC subtypes were identified in which the STING‐high subtype was associated with (1) high immune infiltration, (2) high expression of genes related to MHC and immune checkpoints, and (3) high EMT and ferroptosis score. On the contrary, the STING‐low subtype was enriched with pathways related to DNA damage response (DDR) and cell cycle progression. The association between the DDR pathway activity and the STING‐IFN innate immune response was verified by in vitro experiments in which the inhibition of ATR and TOP1 triggered the expression of genes encoding type I IFN signaling and pro‐inflammatory cytokines/chemokines in a STING‐low SCLC cell line.Conclusion: Our study verifies that activation of the STING‐IFN response by ATR and TOP1 inhibitors might be a therapeutic strategy to improve the response to immune checkpoint therapy in STING‐low SCLC. Furthermore, the combinations of ATR and TOP1 inhibitors can augment tumor inflammation in STING‐low SCLC.

1 July 2018 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
XLXue-Tao Li
Xue-Tao Li
JYJin-Ji Yang
Jin-Ji Yang
YWYI-LONG WU
YI-LONG WU
JHJun Hou
Jun Hou

7 February 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MXMeng Xue
Meng Xue
XLXiaona Lin
Xiaona Lin
QLQiu‐Xiong Lin
Qiu‐Xiong Lin
XPXiaoyong Pu
Xiaoyong Pu
JLJiumin Liu
Jiumin Liu
RCRen Chen
Ren Chen

24 March 2023 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
XLXuetao Li
Xuetao Li
SWShuquan Wei
Shuquan Wei
LDLiaoyuan Deng
Liaoyuan Deng
HTHongYan Tao
HongYan Tao
MLMingkai Liu
Mingkai Liu
JHJun Hou
Jun Hou
Background: Sex-related differences in cancer epidemiology, tumor biology, immune system activity, and pharmacogenomics have been suggested to be important considerations for precision cancer control. Here we elucidated systematically sex biases in genetic variants, gene expression profiles, and immunological landscapes of lung adenocarcinoma patients (LUADs) with different ancestry and smoking status. Methods: Somatic mutation and mRNA expression data of Asian and Non-Asian LUADs were obtained from public databases. Sex-biased genetic mutations, gene expression, biological pathways, and immune infiltration were identified in the context of smoking status and race. Results: Among nonsmokers, male-biased mutations were prevalent in Asian LUADs, while few sex-biased mutations were detected in Non-Asian LUADs. EGFR was the only mutation whose frequency was significantly higher in females than males in both Asian and Non-Asian nonsmokers. More genes exhibited sex-biased expression in Non-Asian LUADs compared to Asian LUADs. Moreover, genes distinctly expressed in females were mainly related to immune-related pathways, whereas those in males were more involved in activation of DNA repair, E2F_targets, and MYC_targets pathways. We also detected sex-specific immune infiltration in the context of genetic variation. In EGFR-mutant LUADs, males had a significantly increased infiltration of CD8 + T cells, whereas resting CD4 + memory T cells were more abundant in females. Additionally, in KRAS-mutant LUADs, CD8 + and CD4 + T cells were more abundant in females than males. In addition, we detected all female patients with high SCGB3A2 expression were exclusively sensitive to immunotherapy, while this phenomenon was not observed in male patients. Conclusions: Our findings provided evidence that sex-related molecular and cellular components are involved in shaping tumor distinct genetic and immune features, which might have important impact on personalized targeted and immune therapy.

1 January 2005 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SSShigeko Sakaguchi
Shigeko Sakaguchi
YYYoshiharu Yokokawa
Yoshiharu Yokokawa
JHJun Hou
Jun Hou
Xiulan ZhangXiulan Zhang
Xiulan Zhang
XLXiangping Li
Xiangping Li
TNTamie Nakajima
Tamie Nakajima
Esophageal cancer is the 6th most common cancer in the world, and genetic factors (p53 mutations) in addition to the environmental factors (food, nutrition, smoking, drinking, etc.) are involved in its development. In this study, the association between the both factors, environmental risk factors for esophageal cancer and p53 mutations, in tumor tissues was investigated in 77 patients living in a high-incidence area and 50 patients living in a low-incidence area in Hebei Province, China. Among these patients, p53 mutations were observed in about 50%, without regional differences in the respective frequencies. G : C > A : T (G to A or C to T) transition mutations were the major type of mutations observed in patients in the high-incidence area (19 patients, 50%), whereas G : C > A : T transitions and insertions were observed with equal frequency (8 patients, 33.3%) in the low-incidence area. As for the association with environmental factors, p53 mutations occurred with higher frequency in patients with a daily intake of spicy foods and in those who used unboiled well water in the low-incidence area. Logistic regression analysis showed no association between food intakes and p53 mutations in high- and low-incidence areas. Thus, higher frequency of spicy food intake and use of unboiled well water may be risk factors of esophageal cancer via p53 mutations in China.

21 January 2026 in Genes, Chromosomes and Cancer
Verified
Journal Article
Open access
XLXuetao Li
Xuetao Li
MYMeifeng Ye
Meifeng Ye
XHXiaomei Huang
Xiaomei Huang
ZHZhong‐Yin Huang
Zhong‐Yin Huang
JZJuan Zhu
Juan Zhu
SWShuquan Wei
Shuquan Wei
Background: Although TP53 and RB1 co‐alterations play critical roles in promoting malignant development and progression, specific inhibitors targeting this co‐alteration are lacking. We performed a pan‐cancer analysis to characterize the biology of TP53 / RB1 co‐alterations and identify therapeutic strategies. Methods: We analyzed mutation data and copy number variation (CNV) data from 42 371 pan‐cancer samples across 26 cancer types from the cBioPortal database. Among them, 2417 tumors with TP53 / RB1 co‐alterations were used for further analysis. We characterized their epidemiology and molecular biology. Therapeutic vulnerabilities of co‐altered tumors were examined using Cancer Cell Line Encyclopedia drug screening datasets. Results: TP53 / RB1 co‐alterations occurred in 5.70% of pan‐cancer cases but exhibit striking heterogeneity across cancer types. Patients harboring co‐alterations had significantly shorter overall survival (OS) in both primary and metastatic settings and poorer response to immune checkpoint inhibitors. Co‐altered tumors displayed frequent alterations in chromatin remodeling genes ( CREBBP , ARID1A , and KMT2D ) and PI3K pathway ( PIK3CA and PTEN ), but with distinct tissue‐specific mutational patterns: EGFR mutations dominated in lung adenocarcinoma (52%), KRAS in pancreatic cancer (88%), and APC in colorectal cancer (77%). Moreover, upregulated genes in co‐altered tumors enriched in cell cycle pathways, DNA repair, and neuronal development, whereas immune/inflammatory signaling was suppressed. Critically, drug screening revealed that co‐altered tumors showed increased sensitivity to CDK, AURKA, and PI3K/mTOR inhibitors, but resistance to MAPK/ERK pathway inhibitors. Conclusions: TP53 / RB1 co‐alterations define an aggressive cancer subset with dysregulated cell cycle/chromatin pathways and reduced immunotherapy response. Targeting CDK, AURKA, or PI3K signaling offers promising therapeutic strategies.